|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||187.56 - 187.56|
|52 Week Range||187.56 - 187.56|
|Beta (5Y Monthly)||1.10|
|PE Ratio (TTM)||17.83|
|Earnings Date||Oct 26, 2021 - Nov 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
PerkinElmer's (PKI) latest acquisition is likely to expand its life science business and enhance its reagents portfolio.
WALTHAM, Mass., September 17, 2021--PerkinElmer today announced it has completed its acquisition of BioLegend, a leading, worldwide provider of life science antibodies and reagents
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.